BNGO

Bionano is an optical-genome-mapping company whose story has fully unraveled into a survival question, and the 10-K says so in plain language: management flags 'our ability to continue as a going concern within 12 months' and warns that if it fails to obtain significant additional financing it 'may seek relief under applicable insolvency laws.' That is not boilerplate here — it is corroborated by the balance sheet, which shows just $2.99M of cash at FY2025 (down 67.4% YoY) against an operating cash burn of -$16.3M. Roughly two months of runway at that burn rate means the company must raise dilutive capital imminently, and the equity base has already been shredded: shares outstanding rose 268.9% in a single year. With a $12.8M market cap, existing holders are first in line to be diluted or wiped out.

The operating business is not growing into the problem. Revenue fell 7.4% to $28.5M, extending a decline from the FY2023 peak of $36.1M, and the underlying volume metrics are flat-to-down — the installed base grew only 4.3% (371→387) and flowcells sold actually fell 0.4% (30,307→30,171). The MD&A points to an Asia-Pacific slowdown tied to government-funding headwinds at manufacturing partners that it does 'not anticipate' will change near-term. So the top line is shrinking, not inflecting. The much-touted 76.4% improvement in net loss (to -$26.4M) is real but is a cost-cut story, not a demand story: R&D was cut 54.1% to $11.4M. Slashing R&D at a technology company fighting for platform adoption borrows from the future to buy a little runway.